IGF-DES
Also known as: IGF-1 DES, Des(1-3) IGF-1
limited human dataWADA bannedNot FDA approvedResearch only
Published Dose Range
Low50 mcg
Typical50-150 mcg
High150 mcg
Post-workout only, injected into trained muscle.
Published Cycle Range
Short4 wks
Typical5 wks
Long6 wks
4-6 weeks.
Off-cycle: 4 weeks
Administration
Routesintramuscular
FrequencyPost-training only
Preferred timingImmediately post-training, into trained muscle
Site-specific injection for localized muscle growth
Safety Profile
Contraindications
- • Cancer history (cell proliferation)
- • Diabetes (glucose)
- • Under 18
Common side effects
- • Localized swelling
Serious risks
- • Hypoglycemia (less than LR3)
Requires monitoring
- • Blood glucose
Pregnancy / breastfeeding
No data — consult clinician
Common Misconceptions
- Localized effect vs LR3's systemic action — different use cases
Commonly Stacked With
IGF-1 LR3BPC-157
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.